Chronic Sialorrhea Market Size Forecasted To Achieve 0.97 Billion By 2029 With Steady Growth

We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Chronic Sialorrhea Market Size and Projected Growth Rate?
The market size for chronic sialorrhea has significantly expanded over the recent past. Its projected growth is from $0.72 billion in 2024 to an elevated figure of $0.76 billion in 2025, with a CAGR of 6.5%. Factors such as an increased occurrence of neurological disorders, population growth, heightened awareness and diagnosis rate, along with a high demand for non-invasive treatment procedures, contribute to the historic period growth.

There is a projected robust growth for the chronic sialorrhea market in the upcoming years. The market is estimated to expand to $0.97 billion by 2029, with a compound annual growth rate (CAGR) of 6.2%. This growth throughout the forecast period is a result of heightened awareness of treatment possibilities, a rising need for effective treatment alternatives, an increased healthcare expenditure, a surge in pediatric cases, and a growing demand for oral gels and liquid. Some of the major trends of the forecast period include the use of telemedicine for remote monitoring, patient-focused care models, pharmaceutical innovations, the combination of speech and occupational therapies, and the creation of long-lasting pharmaceuticals.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21149

What Are the Major Segments in the Chronic Sialorrhea Market?
The chronic sialorrhea market covered in this report is segmented -

1) By Treatment Type: Pharmacological Treatments, Botulinum Toxin Injections, Surgical Interventions, Medical Devices And Assistive Therapies
2) By Route Of Administration: Oral Medications, Injectable Treatments, Topical Applications
3) By Patient Population: Pediatric Patients, Adult Patients
4) By End-User: Hospitals And Specialty Clinics, Rehabilitation Centers, Homecare Settings

Subsegments:
1) By Pharmacological Treatments: Anticholinergic Medications, Antidepressants, Alpha-adrenergic Agonists, Salivary Gland Modulators
2) By Botulinum Toxin Injections: Botulinum Toxin Type A (Botox), Botulinum Toxin Type B (Myobloc), Localized Salivary Gland Injections
3) By Surgical Interventions: Sialendoscopy, Salivary Gland Duct Dilation or Stenting, Parotid Duct Surgery, Submandibular Gland Removal (Sialadenectomy)
4) By Medical Devices And Assistive Therapies: Oral Dryness Devices, Salivary Stimulation Devices, Lip and Mouth Exercises, Artificial Salivary Glands

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21149&type=smp

What Are The Driving Chronic Sialorrhea Market Evolution?
The growing occurrence of neurodegenerative disorders is likely to drive the expansion of the chronic sialorrhea market in the future. Neurodegenerative disorders involve a range of illnesses that are marked by the gradual decay or death of nerves (neurons) in the brain and spinal cord. Genetic and familial influences, environmental aspects, a deeper comprehension of disease mechanisms, long-term health problems, and social and psychological components all contribute to the increase in neurodegenerative disorders. Chronic sialorrhea, a common issue in neurodegenerative disorders such as Parkinson's disease and ALS, requires specific treatments to avoid aspiration, enhance oral function, and improve patient comfort. For example, Parkinson's UK, a charitable organisation based in the UK, reported in September 2023 that around 153,000 people in the UK are currently living with Parkinson's. This figure is expected to rise by 20% to an estimated 172,000 by 2030 due to the aging population. As a result, the escalating frequency of neurodegenerative disorders will fuel the expansion of the chronic sialorrhea market.

Which Firms Dominate The Chronic Sialorrhea Market Segments?
Major companies operating in the chronic sialorrhea market are Pfizer Inc., Eisai Co. Ltd., Ipsen Pharmaceuticals Inc., Aurobindo Pharma Limited, Shionogi Inc., Supernus Pharmaceuticals Inc., Granules India Limited, Hugel Inc., Medy-Tox Inc., Gufic Biosciences Limited, US WorldMeds LLC, Proveca Limited, Neos Therapeutics Inc., Merz Therapeutics GmbH, Taj Pharma India Limited, Meitheal Pharmaceuticals, Clini Experts Services Private Limited, NeuroHealing Pharmaceuticals Inc., ExCEEd Orphan Pharmaceuticals AG, Solstice Neurosciences Inc.

What Trends Are Driving Growth in The Chronic Sialorrhea Market?
Prominent enterprises within the chronic sialorrhea market are concentrating on creating innovative therapeutic approaches, such as oral solutions, to enhance patient adherence and offer less invasive management options for chronic sialorrhea in children, promoting safety and efficacy while cutting down on side effects. An oral solution is a type of medication in liquid form specifically created for oral intake, with the active substance dissolved in a particular solvent for easy consumption. For example, in February 2023, Sialanar (glycopyrronium bromide), a treatment for severe chronic sialorrhea in children with neurological issues, was introduced in France by Proveca Pharma Ltd., a pharmaceutical company based in the UK. This product's standout feature is its liquid formulation, developed to facilitate easy administration and accurate dosage measurement, making it particularly advantageous for pediatric patients who have difficulties with solid medications. It presents a solid safety and efficacy reputation, contributing to enhancing the life quality by controlling excessive drooling, a usual issue in neurodevelopmental conditions such as cerebral palsy.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/chronic-sialorrhea-global-market-report

Which Is The Largest Region In The Chronic Sialorrhea Market?
North America was the largest region in the chronic sialorrhea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic sialorrhea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Chronic Sialorrhea Market?
2. What is the CAGR expected in the Chronic Sialorrhea Market?
3. What Are the Key Innovations Transforming the Chronic Sialorrhea Industry?
4. Which Region Is Leading the Chronic Sialorrhea Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.